Request a demo specialized to your need.
A growing biotech's first few adverse event cases usually get tracked in a shared spreadsheet, an email thread, or a shared inbox. At low volume this works well enough the problems don't show up at case one or ten. They show up later, once volume grows or a regulatory deadline gets missed by a day.
What actually breaks down
No structured validation against E2B(R3) or gateway rules. A spreadsheet doesn't know what a complete, submission-ready case looks like — every completeness check depends entirely on someone remembering to look.
Regulatory deadline tracking relies on memory. Expedited reporting timelines start ticking the moment specific criteria are met, not when someone notices. Manual calendar reminders are a fragile way to manage a hard regulatory requirement.
MedDRA coding has no consistency mechanism. Without database access and a documented process, coding becomes individual judgment applied inconsistently case by case.
No audit trail unless someone builds one manually. 21 CFR Part 11 expects an immutable, timestamped record of who did what and when a spreadsheet doesn't produce that automatically.
Case quality has no consistent standard. Without scoring, some cases get thorough review and others get whatever attention was available that day.
None of it scales past a small number of cases. Tools that work for five cases a month rarely work for fifty manual effort grows faster than volume, not linearly with it.
What generic tools can and can't do
| Requirement | Spreadsheet / Email | Dedicated Safety Software |
|---|---|---|
| E2B(R3) validation | Not available | Automated, real-time |
| Deadline tracking | Manual reminders | System-tracked from trigger |
| Coding consistency | Individual judgment | Database hierarchy |
| Audit trail | Manually documented | Immutable by default |
| Case quality | Inconsistent | Scored before submission |
| Scalability | Breaks down | Designed to handle growth |
Why this matters under ICH E2B(R3), GVP, and 21 CFR Part 11
Regulatory expectations don't scale down for smaller organizations. A biotech with five cases a month still needs the same structural requirements and audit trail as a larger sponsor.
How Cloudbyz's PV tools approach this
AI VigiCheck runs real-time E2B(R3) validation and scores every case before submission. The Medical Coding Assistant pulls MedDRA terms directly from the database hierarchy. E-signature workflows and audit trails are built in by default.
See how Cloudbyz's pharmacovigilance tools support growing safety teams book a demo with your own case data.
Our CEO, Dinesh Kashyap, will be at SCOPE Summit Europe in Barcelona on 13–14 October book time to talk this through. If pharmacovigilance readiness is on your team's radar ahead of ICH E6(R3) and RBQM conversations happening across the industry right now, this is a good one to bring to the table.
Subscribe to our Newsletter
